A clinical trial is a type of research study that helps to find new ways to diagnose, treat, manage or prevent a disease. Clinical trials test new drugs, new ways to do radiation or surgery, or any combination of these.
Clinical trials help us learn about how to make cancer treatment and cancer care better. Most of the treatments prescribed by physicians who went through the clinical trial process at some point; this is how it was determined that they would benefit patients.
In order to conduct clinical trials, investigators must satisfy a number of regulatory requirements and ensure the trial and all its components are approved by a Research Ethics Board.
At WRH, the Cancer Program has a Clinical Trials Department which facilitates meeting these regulatory requirements and also assists in running and managing Clinical Trials. We currently have 5 staff members in the department, four Study Coordinators running the trials and recruiting patients, and one Business Coordinator who manages the day to day and administrative logistics, including study contracts, budgets, training requirements and study startup.
|Study Short Name
|| Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy ± Targeted Therapy
|| Dr. Swati Kulkarni
||A randomized, Double-blind Study Evaluating the efficacy, safety and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)
||Dr. Caroline Hamm
||Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate
|| Dr. Junaid Yousuf
||Medically-inoperative Stage I non-small cell lung cancer comparing stereotactic body radiotherapy vs conventional radiotherapy
||Dr. Khalid Hirmiz
|| A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy
|| Dr. Tarek Elfiki
|| A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab + Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|| Dr. Swati Kulkarni
||A two-part, open-label, randomized, phase II/III study of dinutuximab and irinotecan vs. irinotecan for second line treatment of subjects with relapsed or refractory small cell lung cancer
||Dr. Tarek Elfiki
||A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer
|| Dr. Amin Kay
|| A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
||Dr. Colvin Springer
|NEPA-001 - NOT YET OPEN
|| A Phase IV, Real World Observational Study on the Use of Akynzeo™ (netupitant/palonosetron) for the Prevention of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) over Multiple Cycles
||Dr. Rasna Gupta